

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Ian Turner
Date of Last Notice:	13 April 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Held via broker nominee account.														
Date of change	a) and b) 25 November 2022 c) 28 November 2022														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>209,167</td><td>1,900,002</td></tr><tr><td>Indirect</td><td>304,697</td><td>-</td></tr><tr><td>Total</td><td>513,864</td><td>1,900,002</td></tr></table>				Shares	Options	Direct	209,167	1,900,002	Indirect	304,697	-	Total	513,864	1,900,002
	Shares	Options													
Direct	209,167	1,900,002													
Indirect	304,697	-													
Total	513,864	1,900,002													
Class	a and c) Fully Paid Ordinary Shares b) Listed Options (ASX: RADO)														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>a) 70,422 c) 115,734</td><td>b) 70,422</td></tr><tr><td>Total</td><td>186,156</td><td>70,422</td></tr></table>				Shares	Options	Direct	-	-	Indirect	a) 70,422 c) 115,734	b) 70,422	Total	186,156	70,422
	Shares	Options													
Direct	-	-													
Indirect	a) 70,422 c) 115,734	b) 70,422													
Total	186,156	70,422													

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) \$0.14 per share. b) Non-cash, see 'nature of change' below. c) \$0.11 per share.		
No. of securities held after change		Shares	Options
	Direct	209,167	1,900,002
	Indirect	490,853	70,422
	Total	700,020	1,970,424
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	a) and b) Issue of securities via Retail Entitlement Offer announced 19 October 2022. c) On-Market Trade		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A



The CFO Solution

+ See chapter 19 for defined terms.